OMLYCLO

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Italy, Lithuania, UK.

Active ingredients

The drug OMLYCLO contains one active pharmaceutical ingredient (API):

1	Omalizumab UNII 2P471X1Z11 - OMALIZUMAB
	Omalizumab is a recombinant DNA-derived humanised monoclonal antibody that selectively binds to human immunoglobulin E (IgE) and lowers free IgE levels. The antibody is an IgG1 kappa that contains human framework regions with the complementary-determining regions of a murine parent antibody that binds to IgE.
	Read more about Omalizumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03DX05	Omalizumab	R Respiratory system → R03 Drugs for obstructive airway diseases → R03D Other systemic drugs for obstructive airway diseases → R03DX Other systemic drugs for obstructive airway diseases
Discover more medicines within R03DX05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3074879, 3075027, 3075038, 3075049
FR	Base de données publique des médicaments	66107946, 69603381
IT	Agenzia del Farmaco	051249011, 051249023, 051249035, 051249047
LT	Valstybinė vaistų kontrolės tarnyba	1099866, 1099867, 1099868, 1099869
US	FDA, National Drug Code	72606-035, 72606-036, 72606-052, 72606-053